XTalks

JANUARY 22, 2025

The study included 754 adolescents, comparing immune responses and safety profiles between vaccine and placebo groups. Chikungunya, a mosquito-borne viral disease, causes severe joint pain, fever and rash, with symptoms that can linger for months or even years.

Immune Response 59

Immune Response Vaccination Vaccine Trials 59

XTalks

NOVEMBER 3, 2021

The authorization was based on trial data that showed the vaccine was safe, well-tolerated and induced robust immune responses among children in this age group; side effects were generally mild to moderate. Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer.

Life Science 52

Life Science Drug Delivery Systems Vaccination Vaccine 52

XTalks

JUNE 21, 2024

Dr. Bryan began his career at Schering-Plough, engaging in formulation and drug delivery. Unlike traditional therapies that act on the immune cascade after it has been initiated, Revolo’s treatments act at the very beginning of the immune response.

Development 52

Development Immune Response Drugs Regulation 52

XTalks

MAY 30, 2024

CIDP is a rare autoimmune disorder where the body’s immune system mistakenly attacks its own tissues. The exact cause of this immune response is unknown, and there appears to be no identifiable genetic predisposition to CIDP. Researchers estimate that the incidence of CIDP in the US ranges from 0.8

FDA Approval 40

FDA Approval Immune Response Trials Drug Delivery 40

XTalks

NOVEMBER 5, 2024

Additionally, a collaboration with NurExone is creating an intranasal delivery system for exosome-based therapies targeting spinal cord injuries, with potential expansion into other neurological uses. Polyrizon’s focus on intranasal protection aligns with a rapidly expanding market in drug delivery innovation.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

XTalks

OCTOBER 1, 2024

In the context of asthma, this means potentially restoring the immune response in the respiratory tract to better protect against viral infections that often trigger severe asthma symptoms. These aggregates can trigger unwanted immune responses and reduce transfection efficiency.

Development 52

Development Drugs Immune Response Protein 52

XTalks

OCTOBER 11, 2024

Approved by the US Food and Drug Administration (FDA) in May 2023, Arexvy is designed to prevent lower respiratory tract disease (LRTD) caused by RSV in older adults. The trial assessed vaccine efficacy using RSV-LRTD cases, which refer to lower respiratory tract infections caused by RSV, leading to complications like pneumonia.

Vaccination 104

Vaccination Vaccine Immune Response Trials 104